Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Shutter Connecticut Facility That Builds BeadXpress, Will Consolidate in San Diego

NEW YORK (GenomeWeb News) — Illumina plans to shutter its manufacturing operations in Wallingford, Conn., and fold some of the assets from the space into its San Diego facilities, the company said today.
 
The Wallingford site was originally established in connection with the acquisition of CyVera, and has helped Illumina develop and manufacture the BeadXpress system. The platform debuted last month.
 
Illumina CEO Jay Flatley said that the company decided to consolidate the facility after its recent acquisition of Solexa enabled the company to evaluate “all of our operations.” He said that combining the operations “will provide us with efficiencies from both the manufacturing and development perspective.”
  
It was not immediately clear whether the step would result in lay-offs.
 
Flatley said Illumina will concentrate its R&D and manufacturing work in San Diego and in its facility in Little Chesterford, UK.
 
The company said it will incur roughly $2 million in incremental charges related to the consolidation, and expects that the move will be complete “over the course of 2007."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.